ProMetic Life Sciences (PFSCF) Stock Price, News & Analysis

Company Overview

ProMetic Life Sciences (OTCMKTS:PFSCF) is a Canadian biopharmaceutical company dedicated to the development of innovative small-molecule therapies targeting fibrosis and rare diseases. The company leverages its proprietary platform to identify and optimize compounds that modulate key biological pathways involved in tissue scarring, organ dysfunction and metabolic disorders. ProMetic’s pipeline includes candidates for the treatment of pulmonary fibrosis, chronic kidney disease and orphan indications with high unmet medical needs.

Originally founded in 1988, ProMetic built a strong reputation in plasma protein extraction and purification. The company’s earlier plasma fractionation business was successfully divested to a global plasma products manufacturer in 2016, allowing ProMetic to focus its resources on drug discovery and clinical development. Since that strategic shift, the organization has advanced multiple lead compounds through preclinical and early-stage clinical evaluation.

Headquartered in Laval, Quebec, ProMetic operates research and development facilities in Canada and maintains collaborations with academic and industry partners in North America and Europe. The company’s scientific team applies a multidisciplinary approach—combining medicinal chemistry, pharmacology and translational science—to accelerate the delivery of novel therapies to patients.

ProMetic’s leadership team comprises professionals with deep experience in pharmaceutical research, regulatory affairs and commercialization. The company continues to refine its clinical asset portfolio while exploring strategic partnerships and licensing opportunities to bring its anti-fibrotic and rare disease programs to market.

Key Stats

• Today's Range: $5.47 to $5.47
• 50-Day Range: $5.47 to $5.47
• 52-Week Range: $5.47 to $352.00
• Volume: N/A
• Average Volume: 279 shs
• Market Capitalization: $127.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PFSCF Stock Analysis - Frequently Asked Questions

How have PFSCF shares performed this year?

ProMetic Life Sciences' stock was trading at $5.4670 at the start of the year. Since then, PFSCF stock has increased by 0.0% and is now trading at $5.4670.

How do I buy shares of ProMetic Life Sciences?

Shares of PFSCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:PFSCF
• Previous Symbol: NASDAQ:PFSCF
• CIK: N/A
• Web: www.prometic.com
• Phone: 1-450-781-0115
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$150.73 million
• Net Margins: -894.02%
• Pretax Margin: N/A
• Return on Equity: -3,350.55%
• Return on Assets: -67.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.95
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: $36.55 million
• Price / Sales: 3.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($67.63) per share
• Price / Book: -0.08

Miscellaneous

• Outstanding Shares: 23,313,000
• Free Float: N/A
• Market Cap: $127.45 million
• Optionable: Not Optionable
• Beta: 2.46